In early-phase clinical trials, combinations of an aromatase inhibitor or tamoxifen with HDAC inhibitors such as vorinostat or entinostat demonstrated improvements in overall survival, with the potential to re-sensitize tumours to endocrine therapy in women with resistant disease [61,62]. The gene discussed is CYP19A1; the disease is neoplasm.